Fortis Healthcare quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	2,545	2,167	+17.5%
EBITDA	537	491	+9.5%
EBITDA margin	21.1%	22.7%	−1.5 pts
Profit before tax	359	348	+3.2%
Net profit	273	267	+2.3%
EPS	₹3.53	₹3.45	+2.3%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	2,545	2,365	2,265	2,331	2,167	2,007	1,928	1,988	1,859	1,786	1,680	1,770	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	14.5	4.4	8.3	22.6	15.4	19.8	20.9	13.2	13.0	9.8	6.8	13.5
	2,560	2,369	2,273	2,354	2,182	2,027	1,949	2,002	1,872	1,796	1,686	1,783
	586	521	522	548	518	460	457	466	455	403	389	416
	−12.6	−1.9	−6.1	−8.3	−3.8	3.4	−3.9	−4.9	−2.5	11.1	5.0	−3.5
	404	340	328	317	313	287	294	290	295	272	282	281
	80.4	84.3	85.7	74.9	69.6	67.6	45.2	36.4	35.3	34.7	33.0	31.8
	122	122	120	106	101	102	97.3	95.1	91.0	92.2	86.9	84.1
	1,031	974	916	919	849	821	805	802	768	720	720	746
	2,210	2,039	1,965	1,956	1,847	1,742	1,696	1,685	1,643	1,532	1,516	1,556
	537	532	506	556	491	435	375	435	343	381	284	330
	415	410	386	450	389	333	278	340	252	289	197	246
Profit
	349	330	308	398	335	285	254	317	229	264	171	228
	9.5	−12.5	−45.9	23.5	12.6	−53.6	23.8	−59.8	0.2	3.1	7.7	3.7
	359	318	262	422	348	232	277	257	229	267	179	231
	86.2	65.6	54.9	48.0	39.9	34.4	44.7	51.5	51.7	76.1	38.8	48.8
	4.2	−12.6	13.4	48.6	43.9	14.1	−19.6	16.4	4.4	−7.9	10.1	0.0
	90.4	53.0	68.3	96.6	83.8	48.5	25.1	68.0	56.1	68.2	48.9	48.8
	4.4	6.2	3.5	3.7	2.9	4.6	2.1	4.2	0.6	4.3	4.5	1.3
	273	271	197	329	267	188	254	193	174	203	134	184
	268	265	194	325	264	183	252	189	173	199	130	183
	0.1	2.3	4.5	6.3	−0.5	−3.0	0.5	−0.6	−0.3	0.1	0.1	−0.7
	273	274	202	335	266	185	255	192	174	203	134	183
	266	266	194	322	260	184	248	176	166	179	135	174
	6.4	5.3	3.7	6.9	6.5	4.1	6.4	16.6	7.9	24.4	−0.4	10.2
Per share
	₹3.53	₹3.52	₹2.57	₹4.26	₹3.45	₹2.44	₹3.28	₹2.34	₹2.20	₹2.37	₹1.78	₹2.30
	₹3.53	₹3.52	₹2.57	₹4.26	₹3.45	₹2.44	₹3.28	₹2.34	₹2.20	₹2.37	₹1.78	₹2.30
Other comprehensive income — detail
	0.1	2.3	4.5	6.3	−0.5	−3.0	—	—	—	—	—	—
	−0.4	−3.4	2.0	3.5	−3.1	−5.6	−0.3	−1.8	−0.3	−0.3	−0.4	0.3
	−0.1	−0.6	0.5	0.6	−0.7	−1.7	—	—	—	—	—	—
	—	—	—	—	—	—	−0.0	−0.2	−0.1	0.0	−0.1	−0.3
	0.4	5.1	3.0	—	1.9	0.9	0.7	1.0	−0.1	0.4	0.4	—
	0.0	0.0	0.0	−3.4	0.0	0.0	—	—	—	—	—	—
	—	—	—	—	—	—	0.0	0.0	0.0	0.0	0.0	1.2
	267	268	198	328	260	181	248	175	166	179	135	173
	6.4	5.4	3.5	7.0	6.4	4.1	6.3	16.6	7.8	24.4	−0.6	9.9
Per share — as-filed variants
	₹3.53	₹3.52	₹2.57	₹4.26	₹3.45	₹2.44	₹3.28	₹2.34	₹2.20	₹2.37	₹1.78	₹2.30
	₹3.53	₹3.52	₹2.57	₹4.26	₹3.45	₹2.44	₹3.28	₹2.34	₹2.20	₹2.37	₹1.78	₹2.30
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,972	1,846	1,749	1,792	1,653	1,544	1,475	1,528	1,406	1,372	1,286	1,357
	77.5%	78.1%	77.2%	76.9%	76.3%	76.9%	76.5%	76.8%	75.6%	76.8%	76.6%	76.7%
Adjusted (ex-exceptional items) — derived
	349	330	308	398	335	285	254	317	229	264	171	228
	9.5	−12.5	−45.9	23.5	12.6	−53.6	23.8	−59.8	0.2	3.1	7.7	3.7
	266	282	231	311	257	230	233	237	174	201	129	181
	₹3.44	₹3.66	₹3.01	₹4.02	₹3.33	₹2.99	₹3.00	₹2.87	₹2.20	₹2.34	₹1.71	₹2.26

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

FORTIS₹754.90

Fortis Healthcare Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAPOLLOHOSP MAXHEALTH MEDANTA AUROPHARMA LUPIN ALKEM LAURUSLABS MANKINDMcap ₹56,992 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	1,770.0	1,679.7	1,785.9	1,858.9	1,988.4	1,928.3	2,007.2	2,166.7	2,331.4	2,265.0	2,364.7	2,545.0
Other Income	13.5	6.8	9.8	13.0	13.2	20.9	19.8	15.4	22.6	8.3	4.4	14.5
Total Income	1,783.5	1,686.5	1,795.7	1,871.9	2,001.6	1,949.2	2,027.0	2,182.1	2,354.0	2,273.3	2,369.1	2,559.5
Expenses
+ Purchases of Stock-in-Trade	416.2	388.8	402.6	455.3	465.8	457.4	459.6	517.9	547.8	522.2	520.7	585.6
+ Changes in Inventories	-3.5	5.0	11.1	-2.5	-4.9	-3.9	3.4	-3.8	-8.3	-6.1	-1.9	-12.6
+ Employee Benefit Expense	281.4	282.1	271.5	295.4	290.3	294.2	287.3	312.8	316.6	327.6	339.7	404.4
+ Finance Costs	31.8	33.0	34.7	35.3	36.4	45.2	67.6	69.6	74.9	85.7	84.3	80.4
+ Depreciation & Amortisation	84.1	86.9	92.2	91.0	95.1	97.3	102.2	101.5	105.8	120.1	122.0	121.9
+ Other Expenses	745.7	719.9	719.6	768.1	802.4	805.4	821.4	849.2	918.9	915.6	973.8	1,030.6
Total Expenses	1,555.7	1,515.6	1,531.8	1,642.7	1,685.0	1,695.6	1,741.5	1,847.1	1,955.8	1,965.2	2,038.6	2,210.2
EBITDA	330.2	284.0	381.0	342.5	434.8	375.1	435.5	490.7	556.3	505.7	532.3	537.1
EBIT	246.1	197.1	288.8	251.5	339.8	277.8	333.2	389.2	450.5	385.5	410.4	415.2
Profit
PBT before Exceptional Items	227.7	170.9	263.9	229.3	316.6	253.5	285.5	335.0	398.2	308.1	330.5	349.3
+ Exceptional Items	3.7	7.7	3.1	0.2	-59.8	23.8	-53.6	12.6	23.5	-45.9	-12.5	9.5
Pretax Income	231.4	178.6	267.1	229.5	256.8	277.3	231.9	347.7	421.7	262.2	318.0	358.8
+ Current Tax	48.8	38.8	76.1	51.7	51.5	44.7	34.4	39.9	48.0	54.9	65.6	86.2
+ Deferred Tax	0.0	10.1	-7.9	4.4	16.4	-19.6	14.1	43.9	48.6	13.4	-12.6	4.2
Tax Expense	48.8	48.9	68.2	56.1	68.0	25.1	48.5	83.8	96.6	68.3	53.0	90.4
+ Share of Associates & JVs	1.3	4.5	4.3	0.6	4.2	2.1	4.6	2.9	3.7	3.5	6.2	4.4
Net Income	183.9	134.2	203.1	174.0	193.1	254.3	188.0	266.8	328.8	197.4	271.2	272.8
+ Net Income — Continuing Ops	182.6	129.7	198.8	173.4	188.9	252.2	183.4	263.9	325.1	193.9	265.0	268.4
+ Other Comprehensive Income	-0.7	0.1	0.1	-0.3	-0.6	0.5	-3.0	-0.5	6.3	4.5	2.3	0.1
Total Comprehensive Income	183.3	134.3	203.2	173.7	192.5	254.8	185.0	266.3	335.1	201.9	273.5	272.9
Net Income to Common	173.7	134.7	178.7	165.8	175.9	247.9	183.9	260.3	321.9	193.7	265.9	266.4
Minority Interest	10.2	-0.4	24.4	7.9	16.6	6.4	4.1	6.5	6.9	3.7	5.3	6.4
Per Share
Basic EPS	2.30	1.78	2.37	2.20	2.34	3.28	2.44	3.45	4.26	2.57	3.52	3.53
Diluted EPS	2.30	1.78	2.37	2.20	2.34	3.28	2.44	3.45	4.26	2.57	3.52	3.53
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-3.0	-0.5	6.3	4.5	2.3	0.1
+ Items NOT to be Reclassified to P&L	0.3	-0.4	-0.3	-0.3	-1.8	-0.3	-5.6	-3.1	3.5	2.0	-3.4	-0.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-1.7	-0.7	0.6	0.5	-0.6	-0.1
+ Tax on Items NOT to be Reclassified — alt tag	-0.3	-0.1	0.0	-0.1	-0.2	-0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	0.4	0.4	-0.1	1.0	0.7	0.9	1.9	—	3.0	5.1	0.4
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.0	0.0	-3.4	0.0	0.0	0.0
+ Tax on Items to be Reclassified — alt tag	1.2	0.0	0.0	0.0	0.0	0.0	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	173.4	134.9	178.9	165.6	175.2	248.5	180.9	259.9	328.1	198.4	268.2	266.5
Comprehensive Income — Non-controlling Interests	9.9	-0.6	24.4	7.8	16.6	6.3	4.1	6.4	7.0	3.5	5.4	6.4
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.30	1.78	2.37	2.20	2.34	3.28	2.44	3.45	4.26	2.57	3.52	3.53
Diluted EPS — Continuing Operations	2.30	1.78	2.37	2.20	2.34	3.28	2.44	3.45	4.26	2.57	3.52	3.53
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,357.2	1,285.9	1,372.2	1,406.0	1,527.6	1,474.8	1,544.2	1,652.6	1,791.9	1,748.9	1,845.8	1,972.1
Gross Margin %	76.68	76.56	76.84	75.64	76.82	76.48	76.93	76.27	76.86	77.21	78.06	77.49
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	227.7	170.9	263.9	229.3	316.6	253.5	285.5	335.0	398.2	308.1	330.5	349.3
− Exceptional Items (reconciliation)	3.7	7.7	3.1	0.2	-59.8	23.8	-53.6	12.6	23.5	-45.9	-12.5	9.5
Net Income Adj (tax-effected)	181.0	128.6	200.8	173.8	237.0	232.7	230.4	257.2	310.7	231.4	281.6	265.7
EPS Adj	2.26	1.71	2.34	2.20	2.87	3.00	2.99	3.33	4.02	3.01	3.66	3.44
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Filed Debt Equity	—	—	—	—	—	0.00	0.27	0.28	0.33	0.35	0.34	0.31
Filed Dscr	—	—	—	—	—	3.00	8.49	5.92	1.68	1.77	1.24	1.06
Filed Iscr	—	—	—	—	—	9.00	6.81	7.32	7.78	6.04	6.44	6.91
Paid Up Equity Capital	755.0	755.0	755.0	755.0	755.0	755.0	755.0	755.0	755.0	755.0	755.0	755.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Fortis Healthcare Q2 FY27 results date

Fortis Healthcare (NSE: FORTIS) will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, according to the board-meeting notice it filed on 29 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹266 crore, up 2.3% from ₹260 crore in Q1 FY26 and up 0.2% from ₹266 crore in Q4 FY26. Revenue from operations was ₹2,545 crore, up 17.5% year on year and up 7.6% from the previous quarter.

Board-meeting notice filed: 29 October 2026
Q2 FY26 results (a year earlier): 11 November 2025
Q1 FY27 results (the latest): 6 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 5 November 2026Thursday · notice filed 29 Oct
Q1 FY27 net profit: ₹266 Cr+2.3% vs Q1 FY26+0.2% vs Q4 FY26
Q1 FY27 revenue: ₹2,545 Cr+17.5% vs Q1 FY26+7.6% vs Q4 FY26
Q1 FY27 operating margin: 16.3%−1.6 pts vs Q1 FY26−1.0 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹322 CrRevenue ₹2,331 Cr
Q1 FY27 EPS (basic): ₹3.53

Questions

When will Fortis Healthcare announce its Q2 FY27 results?

On 5 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 29 October 2026). Last year it reported Q2 FY26 on 11 November 2025.

What will Fortis Healthcare's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹322 crore and revenue from operations ₹2,331 crore. The latest quarter, Q1 FY27, had a net profit of ₹266 crore and revenue of ₹2,545 crore.

What were Fortis Healthcare's Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹266 crore, up 2.3% from ₹260 crore in Q1 FY26 and up 0.2% from ₹266 crore in Q4 FY26. Revenue from operations was ₹2,545 crore, up 17.5% year on year and up 7.6% from the previous quarter.

How has Fortis Healthcare's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹322 crore in Q2 FY26, ₹194 crore in Q3 FY26, ₹266 crore in Q4 FY26 and ₹266 crore in Q1 FY27. That is ₹1,048 crore over the four quarters, up 20.7% from ₹868 crore in the four quarters before. Revenue from operations: ₹2,331 crore, ₹2,265 crore, ₹2,365 crore and ₹2,545 crore.

What was Fortis Healthcare's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹1,042 crore in FY26 (April 2025–March 2026), up 34.6% from ₹774 crore in FY25. It was ₹599 crore in FY24 and ₹589 crore in FY23: up 77.0% over three years, 21.0% a year on average.

What was Fortis Healthcare's revenue in FY26?

Revenue from operations was ₹9,128 crore in FY26 (April 2025–March 2026), up 17.3% from ₹7,783 crore in FY25. It was ₹6,893 crore in FY24 and ₹6,298 crore in FY23: up 44.9% over three years, 13.2% a year on average.

Where do these Fortis Healthcare figures come from?

From Fortis Healthcare's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.